Tulathromycin

Tulathromycin, sold under the brand name Draxxin and the top generic is branded under the name Tulieve,from Norbrook Ltd., is a macrolide antibiotic used to treat bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs.[3][4]

Tulathromycin
Clinical data
Trade namesDraxxin, Tulissin
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Intramuscular, subcutaneous
ATCvet code
Legal status
Legal status
Identifiers
IUPAC name
  • (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-Ο-methyl-4-C-[(propylamino)methyl]-α-L-ribo-hexopyrano-syl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]-oxy]-1-oxa-6-azacyclopentadecan-15-one
CAS Number
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.166.454
Chemical and physical data
FormulaC41H79N3O12
Molar mass806.092 g·mol−1
3D model (JSmol)
SMILES
  • CCCNCC1(C(OC(CC1(C)OC)OC2C(C(C(CC(NC(C(C(C(OC(=O)C2C)CC)(C)O)O)C)C)(C)O)OC3C(C(CC(O3)C)N(C)C)O)C)C)O
InChI
  • InChI=1S/C40H77N3O12/c1-15-17-41-21-40(49)27(8)52-30(20-38(40,10)50-14)54-32-24(5)34(55-36-31(44)28(43(12)13)18-23(4)51-36)37(9,47)19-22(3)42-26(7)33(45)39(11,48)29(16-2)53-35(46)25(32)6/h22-34,36,41-42,44-45,47-49H,15-21H2,1-14H3/t22-,23-,24+,25-,26-,27+,28+,29-,30+,31-,32+,33-,34-,36+,37-,38-,39-,40+/m1/s1 Y
  • Key:HWATWVYEWMIMSO-FROLMUNOSA-N Y

  • InChI=1S/C41H79N3O12/c1-15-17-42-22-41(50)28(8)53-31(20-39(41,10)51-14)55-33-25(5)35(56-37-32(45)29(44(12)13)18-24(4)52-37)38(9,48)19-23(3)21-43-27(7)34(46)40(11,49)30(16-2)54-36(47)26(33)6/h23-35,37,42-43,45-46,48-50H,15-22H2,1-14H3/t23-,24-,25+,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,37+,38-,39-,40-,41+/m1/s1
  • Key:GUARTUJKFNAVIK-QPTWMBCESA-N
  (verify)

It is supplied as a solution for injection containing 100 mg of the drug.[5]

Medical uses

Tulathromycin is indicated for:

Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis sensitive to tulathromycin.[1]

Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin.[1]

Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis, and Bordetella bronchiseptica sensitive to tulathromycin.[1]

Sheep: Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus requiring systemic treatment.[1]

Society and culture

Tulathromycin (brand name Draxxin) was approved for medical use in the European Union in November 2003.[1]

Tulathromycin (brand names Tulissin and Tulaven) was approved for medical use in the European Union in April 2020.[6][7]

On 16 July 2020, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted positive opinions, recommending the granting of marketing authorizations for the veterinary medicinal products Increxxa and Tulinovet solutions for injection for cattle, pigs and sheep.[8][9] The applicant for Increxxa is Elanco GmbH.[8] The applicant for Tulinovet is VMD N.V.[9]

Brand names

It is marketed by Pfizer Inc. under the brand name Draxxin.

Generic names

It is marketed by Bimeda Inc. under the brand name Macrosyn.

References
  1. "Draxxin EPAR". European Medicines Agency (EMA). Retrieved 20 August 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. "Tulinovet EPAR". European Medicines Agency. Retrieved 11 October 2021.
  3. Evans NA (2005). "Tulathromycin: an overview of a new triamilide antibiotic for livestock respiratory disease". Veterinary Therapeutics: Research in Applied Veterinary Medicine. 6 (2): 83–95. PMID 16094557.
  4. Villarino N, Brown SA, Martín-Jiménez T (November 2013). "The role of the macrolide tulathromycin in veterinary medicine". Veterinary Journal. London, England. 198 (2): 352–7. doi:10.1016/j.tvjl.2013.07.032. PMID 24268476.
  5. Draxxin Archived 2006-10-24 at the Wayback Machine at draxxin.com
  6. "Tulissin EPAR". European Medicines Agency (EMA). Retrieved 20 August 2020.
  7. "Tulaven EPAR". European Medicines Agency (EMA). Retrieved 20 August 2020.
  8. "Increxxa: Pending EC decision". European Medicines Agency. 17 July 2020. Retrieved 17 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. "Tulinovet: Pending EC decision". European Medicines Agency. 17 July 2020. Retrieved 17 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.